Global Generalized Anxiety Disorder Treatment Industry is anticipated to witness substantial growth, reaching a 9% CAGR by 2033 based on FMI’s analysis  

Generalized Anxiety Disorder Treatment Industry
Generalized Anxiety Disorder Treatment Industry

The global generalized anxiety disorder treatment industry is projected to reach a market size of US$ 1800 million in 2023 and US$ 4261.25 million by 2033, growing at a CAGR of 9% over that time. The market for treating generalised anxiety disorder is expanding due to the rising incidence of mental health issues and the wide range of available therapies. From 2018 to 2022, the market for treating generalised anxiety disorder experienced a CAGR of 5.1%.

Growth of the market can be attributed to increasing prevalence and awareness of mental health issues. In addition, research and development to offer therapeutic treatments along with better antidepressants are boosting the growth of the market.

Get your Sample Report with Latest Market Information! https://www.futuremarketinsights.com/reports/sample/rep-gb-16745

The most common treatment options for GAD include medications such as antidepressants, benzodiazepines, and beta-blockers, as well as psychotherapy such as cognitive-behavioral therapy (CBT) and mindfulness-based therapy. The demand for these treatments is expected to increase as more people seek help for their GAD symptoms.

The Generalized Anxiety Disorder Treatment Market is also expected to benefit from the growing use of digital technologies such as telemedicine and mobile health apps. These technologies can help to increase access to treatment for people who may not have easy access to mental health services.

Key Takeaways from the Market Study:

  • The generalized anxiety disorder treatment market is expected to grow at a value of 9% CAGR in the forecast period 2023 to 2033.
  • By drug class, antidepressants are expected to possess 48% market share for generalized anxiety disorder treatment market in 2023.
  • North America is expected to possess 47% market share for generalized anxiety disorder treatment market in 2023.
  • Asia Pacific is expected to possess 42% market share for generalized anxiety disorder treatment market in 2023.

“The market for psychotherapy is expected to grow, driven by the increasing awareness of the importance of mental health and the growing availability of online therapy services.” states an FMI analyst

Feel Free To Reach Out To Our Analyst For Any Queries You Might Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16745

Competitive Landscape:

Key players in the generalized anxiety disorder treatment market are MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Bristol-Myers Squibb and Actavis Pharmaceutical Company

  • MindMed has developed a digital therapeutics platform called “Lytica” that aims to improve mental health outcomes for patients with anxiety disorders. The platform uses cognitive-behavioral therapy (CBT) techniques to help patients manage their symptoms and improve their mental well-being.
  • Actavis offers a number of drugs that are commonly used in the treatment of GAD, including benzodiazepines like clonazepam and lorazepam. These drugs work by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that has a calming effect on the brain.

Key Segments Profiled in the Generalized Anxiety Disorder Treatment Industry Survey:

Drug Class:

  • Antidepressant
  • Buspirone
  • Benzodiazepines

Therapies:

  • Interpersonal Therapy
  • Behavioural Therapy
  • Cognitive Behaviour Therapy
  • Mindfulness Based Cognitive Therapy

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Customization Unleashed: Learn How to Stand Out in a Competitive Landscape! https://www.futuremarketinsights.com/customization-available/rep-gb-16745

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these